About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker IBRX · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Nov 2, 2026Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel…
NCT06745908 · NSCLC Stage IV
N-803, Tislelizumab
IBRX
ImmunityBio, Inc.
Phase 3Recruiting507Sep 2028Registry ↗
Nov 2, 2026QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors
NCT04898543 · Metastatic Solid Tumor
M-CENK, Suspension for Infusion, Cryopreserved (M-CENK) (Co…
IBRX
ImmunityBio, Inc.
Phase 1Active, not recruiting50Feb 2, 2026Registry ↗
Nov 2, 2026Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy f…
NCT04390399 · Pancreatic Cancer
N-803, Aldoxorubicin HCl
IBRX
ImmunityBio, Inc.
Phase 2Active, not recruiting328Oct 13, 2025Registry ↗
Sep 25, 2026NAI Plus Standard of Care Compared With Placebo Plus Standard of Care in Critically Ill Adults With…
NCT07783789 · Sepsis
Nogapendekin alfa inbakicept (NAI), Placebo
IBRX
ImmunityBio, Inc.
Phase 2Not yet recruiting50May 12, 2028Registry ↗
Sep 24, 2026N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer
NCT07217496 · Metastatic Urothelial Carcinoma, Urothelial Carcinoma
Nogapendekin Alfa Inbakicept (NAI), enfortumab vedotin (EV)
IBRX
ImmunityBio, Inc.
Phase 1Not yet recruiting18Jan 2028Registry ↗
Sep 24, 2026A Study to Examine Anktiva for the Treatment of COVID-19.
NCT07123727 · Long COVID, Long COVID Syndrome
Anktiva
IBRX
ImmunityBio, Inc.
Phase 2Recruiting40Mar 2027Registry ↗
Aug 31, 2026IBRX-042 In Participants With HPV-Associated Tumors
NCT05976828 · HPV-Related Carcinoma
IBRX-042
IBRX
ImmunityBio, Inc.
Phase 1Active, not recruiting12Sep 2, 2027Registry ↗
Aug 28, 2026Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept, Sotevtamab, and Zab…
NCT07488884 · Pancreatic Cancer Resectable, Pancreatic Cancer
Nogapendekin Alfa Inbakicept (N803), Sotevtamab
IBRX
ImmunityBio, Inc.
Phase 1Withdrawn0Jun 1, 2027Registry ↗
Aug 19, 2026A Safety and Efficacy Study of CD-19 t-haNK in Patients With B-cell Acute Lymphoblastic Leukemia
NCT07556757 · B-ALL, Leukemia
CD19 t-haNK
IBRX
ImmunityBio, Inc.
Phase 1Terminated4Jul 1, 2026Registry ↗
Jul 10, 2026Study for Participants With Relapsed/Refractory Non-Hodgkin Lymphoma
NCT06334991 · Non-Hodgkin Lymphoma Refractory/ Relapsed
CD19 t-haNK
IBRX
ImmunityBio, Inc.
Phase 1Active, not recruiting20Oct 2027Registry ↗
Jul 1, 2026A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15…
NCT06710288 · Platinum-resistant Ovarian Cancer
Gemcitabine, N-803
IBRX
ImmunityBio, Inc.
Phase 2Recruiting20May 2027Registry ↗
Jul 1, 2026N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma
NCT06061809 · Glioblastoma
Bevacizumab, PD-L1 t-haNK
IBRX
ImmunityBio, Inc.
Phase 2Active, not recruiting34Dec 31, 2029Registry ↗
Jun 22, 2026Phase 3 Study of Nogapendekin Alfa Inbakicept Plus Standard of Care vs Standard of Care in First-Li…
NCT07524257 · NSCLC (Advanced Non-small Cell Lung Cancer), Metastatic NSC…
Drug: Nogapendekin alfa inbakicept (NAI), Pembrolizumab
IBRX
ImmunityBio, Inc.
Phase 3Withdrawn0May 15, 2029Registry ↗
Jun 4, 2026Phase 2 Study of NAI, HPV Vaccine, and Nab-Paclitaxel in HPV-Positive Oropharyngeal Cancer Followed…
NCT07628062 · HPV-Positive Oropharyngeal Squamous Cell Carcinoma, Orophar…
Nogapendekin Alfa Inbakicept (NAI), hAd5-HPV Vaccine (IBRX-…
IBRX
ImmunityBio, Inc.
Phase 2Not yet recruiting70Dec 31, 2030Registry ↗
May 26, 2026Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer
NCT03520686 · Non Small Cell Lung Cancer
NAI + Pembrolizumab, NAI + Nivolumab + Ipilimumab
IBRX
ImmunityBio, Inc.
Phase 3Terminated102Oct 13, 2025Registry ↗
May 19, 2026ANKTIVA Plus BCG Versus BCG Monotherapy In Participants With BCG-Naïve/BCG-Exposed High-Grade Non-M…
NCT07551544 · NMIBC
BCG (50 mg) plus ANKTIVA (400 µg), BCG (50 mg)
IBRX
ImmunityBio, Inc.
Phase 3Withdrawn0May 2032Registry ↗
May 14, 2026ResQ132EX-NMIBC: Expanded Access Use of Recombinant Bacillus Calmette-Guérin in Nonmuscle Invasive…
NCT06810141 · NMIBC
rMBCG
IBRX
ImmunityBio, Inc.
—Available——Registry ↗
May 11, 2026NAI for Sepsis With Persistent Lymphopenia
NCT07578558 · Sepsis, Septic Shock
Nogapendekin alfa inbakicept (NAI), Standard of Care (SOC)
IBRX
ImmunityBio, Inc.
Phase 2Not yet recruiting50Aug 3, 2027Registry ↗
May 11, 2026A Study to Assess Anktiva in Patients With Long Covid-19.
NCT07108036 · Long COVID
N-803 (IL-15 Superagonist)
IBRX
ImmunityBio, Inc.
Phase 2Recruiting20Oct 2026Registry ↗
May 8, 2026Nogapendekin Alfa-Inbakicept and iNKT Cells for Critically Ill Adults With Severe Community-Acquire…
NCT07492888 · Acute Respiratory Distress Syndrome, Severe Community-Acqui…
Nogapendekin Alfa-Inbakicept (NAI), Allogeneic invariant Na…
IBRX
ImmunityBio, Inc.
Phase 2Withdrawn0Nov 15, 2026Registry ↗
May 8, 2026Study of Nogapendekin Alfa Inbakicept and iNKT Cells in Critically Ill Adults With Severe Community…
NCT07492875 · Community-Acquired Pneumonia (CAP), Acute Respiratory Distr…
Nogapendekin alfa inbakicept (NAI), agenT-797
IBRX
ImmunityBio, Inc.
Phase 3Withdrawn0Apr 15, 2029Registry ↗
May 5, 2026Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With…
NCT06765954 · High-risk Prostate Cancer
N-803 (IL-15 Superagonist), ETBX-071 (PSA-based Oncolytic V…
IBRX
ImmunityBio, Inc.
Phase 2Withdrawn0Jan 31, 2031Registry ↗
May 5, 2026Immunotherapy Before and After Surgery
NCT06765902 · High-risk Prostate Cancer
N-803, ETBX-071
IBRX
ImmunityBio, Inc.
Phase 2Withdrawn0Jan 31, 2031Registry ↗
May 4, 2026Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma
NCT07125872 · Relapsed B-Cell Non Hodgkin Lymphoma
CD19 t-haNK- IV Administration
IBRX
ImmunityBio, Inc.
Phase 2Recruiting20May 25, 2027Registry ↗
Apr 29, 2026Follow up of Intravesical N-803 Plus BCG in BCG-Naive Non-Muscle Invasive Bladder Cancer (NMIBC)
NCT05981131 · Non Muscle Invasive Bladder Cancer
N803 plus Bacillus Calmette-Guerin (BCG)
IBRX
ImmunityBio, Inc.
—Active, not recruiting6Aug 30, 2033Registry ↗
Apr 15, 2026HCW9218 for Advanced Pancreatic Cancer
NCT05304936 · Advanced Pancreatic Carcinoma
HCW9218, Gemcitabine (GEM)
IBRX
ImmunityBio, Inc.
Phase 1/2Completed21Feb 15, 2025Registry ↗
Apr 1, 2026Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma
NCT05618925 · Non Hodgkin's Lymphoma Refractory/Relapsed
N803, CD19t-haNK suspension
IBRX
ImmunityBio, Inc.
Phase 1Recruiting20May 15, 2026Registry ↗
Apr 1, 2026QUILT-3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers
NCT04050709 · Locally Advanced Solid Tumor, Metastatic Cancer
PD-L1 t-haNK
IBRX
ImmunityBio, Inc.
Phase 1Completed16Mar 30, 2021Registry ↗
Mar 31, 2026A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladde…
NCT02138734 · Non-muscle Invasive Bladder Cancer
BCG (50mg/instillation) + N-803 (400 μg/instillation), BCG…
IBRX
ImmunityBio, Inc.
Phase 1/2Active, not recruiting369Sep 30, 2026Registry ↗
Mar 27, 2026ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible…
NCT06800963 · NMIBC
Intravesical Recombinant Mycobacterium (rMBCG)
IBRX
ImmunityBio, Inc.
Phase 1/2Recruiting40Feb 2028Registry ↗
Mar 17, 2026Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma
NCT07477366 · Relapsed B-Cell Non-Hodgkin Lymphoma
CD19 t-haNK- IV Administration, N-803
IBRX
ImmunityBio, Inc.
Phase 2Not yet recruiting20Dec 2027Registry ↗
Jan 14, 2026QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatm…
NCT03228667 · Non-Small Cell Lung Cancer, Small Cell Lung Cancer
N-803 + Pembrolizumab, N-803 + Nivolumab
IBRX
ImmunityBio, Inc.
Phase 2Active, not recruiting40Aug 31, 2029Registry ↗
Oct 16, 2025Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papil…
NCT06829823 · Non-muscle Invasive Bladder Cancer (NMIBC)
N-803 and BCG, N-803 and Gemcitabine
IBRX
ImmunityBio, Inc.
Phase 2Not yet recruiting20Nov 2026Registry ↗
Oct 16, 2025QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combina…
NCT03022825 · Bladder Cancer
N-803 and BCG, N-803
IBRX
ImmunityBio, Inc.
Phase 2/3Active, not recruiting190Oct 1, 2024Registry ↗
Oct 14, 2025Expanded Access Use of Nogapendekin-alfa Inbakicept in the Reversal and Maintenance of Absolute Lym…
NCT06956547 · Lymphopenia
nogapendekin-alfa inbakicept
IBRX
ImmunityBio, Inc.
—Available——Registry ↗
Oct 14, 2025Single Center Study Of N-803 Stimulation On Expansion, Enrichment, Proliferation Of Natural Killer…
NCT06040918 · Healthy Subjects
N-803
IBRX
ImmunityBio, Inc.
Phase 1Completed10Sep 3, 2024Registry ↗
Mar 11, 2025THEMBA II T-Cell Vaccine: Vaccination With saRNA COVID-19 Vaccines
NCT05370040 · COVID-19
AAHI-SC2 Vaccine, AAHI-SC3 Vaccine
IBRX
ImmunityBio, Inc.
Phase 1/2Terminated60Mar 11, 2024Registry ↗
Feb 24, 2025QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Re…
NCT03169790 · Non Hodgkin Lymphoma
avelumab, bevacizumab
IBRX
ImmunityBio, Inc.
Phase 1/2Withdrawn0Jan 2019Registry ↗
Feb 24, 2025QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy…
NCT03169764 · Head and Neck Squamous Cell Carcinoma
Avelumab, Bevacizumab
IBRX
ImmunityBio, Inc.
Phase 1/2Withdrawn0Jan 2019Registry ↗
Feb 21, 2025COVID-19 Subcutaneously and Orally Administered Supplemental Vaccine Boost to Enhance T Cell Protec…
NCT04845191 · Covid19
hAd5-S-Fusion+N-ETSD vaccine
IBRX
ImmunityBio, Inc.
Phase 1/2Withdrawn0Dec 2021Registry ↗
Feb 21, 2025COVID-19 Supplemental Vaccine Boost to Enhance T Cell Protection in Those Who Have Already Received…
NCT04843722 · Covid19
hAd5-S-Fusion+N-ETSD vaccine
IBRX
ImmunityBio, Inc.
Phase 1/2Withdrawn0Dec 2021Registry ↗
Feb 21, 2025QUILT-3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma
NCT04052061 · Diffuse Large B Cell Lymphoma, Large-cell Lymphoma
CD19 t-haNK
IBRX
ImmunityBio, Inc.
Phase 1Withdrawn0Sep 18, 2021Registry ↗
Feb 21, 2025QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma.
NCT03647423 · Chordoma, Unresectable Malignant Neoplasm
Aldoxorubicin Hydrochloride, ALT-803
IBRX
ImmunityBio, Inc.
Phase 1/2Withdrawn0Aug 31, 2020Registry ↗
Feb 21, 2025QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus…
NCT03574649 · Non Small Cell Lung Cancer
Nab-paclitaxel, Cisplatin
IBRX
ImmunityBio, Inc.
Phase 2Withdrawn0Aug 2018Registry ↗
Feb 21, 2025QUILT-3.088: NANT Pancreatic Cancer Vaccine
NCT03563144 · Metastatic Pancreatic Cancer
Gemcitabine, Nab-paclitaxel
IBRX
ImmunityBio, Inc.
Phase 2Withdrawn0Dec 30, 2019Registry ↗
Feb 21, 2025QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine
NCT03554109 · Triple Negative Breast Cancer (TNBC)
Leucovorin, 5-Fluorouracil
IBRX
ImmunityBio, Inc.
Phase 2Withdrawn0Jun 2020Registry ↗
Feb 21, 2025QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ova…
NCT03197584 · Ovarian Cancer
Avelumab, Bevacizumab
IBRX
ImmunityBio, Inc.
Phase 1/2Withdrawn0Feb 2019Registry ↗
Feb 21, 2025QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial…
NCT03197571 · Urothelial Carcinoma
avelumab, bevacizumab
IBRX
ImmunityBio, Inc.
Phase 1/2Withdrawn0Jan 2019Registry ↗
Feb 21, 2025QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjec…
NCT03175666 · Triple Negative Breast Cancer
avelumab, bevacizumab
IBRX
ImmunityBio, Inc.
Phase 1/2Withdrawn0Jan 2019Registry ↗
Feb 21, 2025QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recur…
NCT03169777 · Colorectal Cancer
avelumab, bevacizumab
IBRX
ImmunityBio, Inc.
Phase 1/2Withdrawn0Jan 2019Registry ↗

The newest 50 items, most recent first. Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:45 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances